BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimers patients
By, Admin1 min read
Share
BioXcel Therapeutics has announced that the first patient involved in the phase 3 TRANQUILITY 2 study of BXCL501 has received a dose for the acute treatment of agitation in patients with Alzheimer
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
